Ascentra · A²I™ × Aesculytics
Know if your evidence plan gets you funded — before you lock the protocol
Evidence gap analysis and in silico stress-testing for medical device founders, mapped to MSAC, NICE, and PHARMAC reimbursement standards.
MSAC · AustraliaNICE · UKPHARMAC · NZEquity Gate · Non-overridable
One interface. Two engines. One report.
A²I™ evidence gap analysis, paired with Aesculytics in silico stress-testing, for pre-protocol device founders.
01
Evidence Gap Analysis
Six-stage A²I™ methodology flags where your evidence plan will fail MSAC, NICE, or PHARMAC — before the study is designed.
02
In Silico Stress-Test
Aesculytics computational modelling stress-tests high-fragility claims, including bioequivalence, ahead of trial design.
03
Evidence Claim Strength Report
A single investor-ready report — evidence position, remedial actions, mapped to named MSAC/NICE/PHARMAC standards.